# Precede Biosciences

> Precede Biosciences is a Boston precision diagnostics and data company that profiles epigenomic signals in cell-free DNA from 1 mL of plasma to infer gene expression, pathway activity and cell states. It works with biopharmaceutical developers and academic researchers on patient selection, drug response and resistance, while advancing diagnostic applications for clinical trials.

- **Founded:** 2021
- **Headquarters:** Boston, United States
- **Founders:** Rehan Verjee (Co-founder and Chief Executive Officer), Sylvan Baca (Scientific co-founder), Matthew Freedman (Scientific co-founder), Toni Choueiri (Scientific co-founder)
- **Products:** Precede Bio Insight™, Precede Bio Dx™, Comprehensive epigenomic liquid biopsy collaborations
- **Notable:** Emerged from stealth in October 2023 with a research-use-only platform and US$57 million in combined backing., Reported more than 7,000 genome-wide transcriptional profiles generated by its 2023 launch., Foundational proof-of-concept research published in Nature Medicine in October 2023.

## Products & services

- **Precede Bio Insight™** — Research-use-only plasma-based comprehensive epigenomic profiling with machine learning to infer genome-wide transcriptional activation and tumor-specific gene expression; used in R&D collaborations. Named product launched at AACR in April 2026.
- **Precede Bio Dx™** — Company-described clinical-trial offering for non-invasive patient selection based on target expression, pathway activity and cell states; no general clinical approval inferred.
- **Comprehensive epigenomic liquid biopsy collaborations** — Assay and computational analysis collaborations with biopharmaceutical developers and academic researchers, available as a research-use-only platform from October 2023.

## Achievements

- Emerged from stealth in October 2023 with a research-use-only platform and US$57 million in combined backing.
- Reported more than 7,000 genome-wide transcriptional profiles generated by its 2023 launch.
- Foundational proof-of-concept research published in Nature Medicine in October 2023.
- Presented prediction of expression for more than 2,500 disease-relevant tumor genes at AACR 2025.
- Launched the named Precede Bio Insight product in April 2026.

## Latest updates

- **2026-05** — Presented ASCO research on MET-related functional biology, tepotinib sensitivity/resistance and progression on osimertinib in advanced NSCLC.
- **2026-04** — Launched Precede Bio Insight at AACR with studies involving breast and prostate cancer, ER dependence and multiplexed target expression.
- **2026-01** — Announced US$63.5 million Series B equity plus a US$20 million strategic credit facility; Wouter Meuleman joined the board.

## Links

- Website: https://www.precede.bio/
- LinkedIn: https://www.linkedin.com/company/precedebiosciences/
- Twitter/X: https://twitter.com/Precede_Bio
- YouTube: https://www.youtube.com/channel/UCzPNdtdpYa68IYKG_BnlbIw

---

Profile page: https://yespress.io/precede-biosciences
Published by YesPress — https://yespress.io
Last updated: 2026-10-03